Skip to main content

Pulmonary Arterial Hypertension - A Deeper Dive

Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first live webinar provides an in-depth discussion of the new thresholds for the diagnosis of PAH, and differential diagnostic considerations, along with the emerging data on the optimal management of patients with PAH. This webinar provides a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.

Commercial Support
This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Bayer HealthCare Pharmaceuticals Inc.